Skip to main content Accessibility help
×
Home

The use of selective serotonin reuptake inhibitors in geriatric depression: a review of the literature

  • Richard Marc Patel (a1) and George T Grossberg (a2)

Abstract

  • An abstract is not available for this content so a preview has been provided below. Please use the Get access link above for information on how to access this content.

Copyright

Corresponding author

Richard Marc Patel, 45 Montcalm Street, San Francisco, California 94110, USA.

References

Hide All
1Schnieder, JS, Reynolds, CF, Lebowitz, BD, Friedhoff, AJ. Diagnosis and treatment of depression in later life. Washington, DC: American Psychiatric Press, 1994.
2Lapin, IP, Oxenkrug, GF. Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet 1969; i: 132–36.
3Meltzer, HY, Lowy, MT. The serotonin hypothesis of depression. In: Meltzer, HY ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 513–26.
4Koenig, HG, Blazer, DG. Epidemiology of geriatric affective disorders. Clin Geriatric Med 1992; 8: 235–51.
5Snowdon, J. The prevalence of depression in old age. Int J Geriatric Psychiatry 1990; 5: 141–44.
6Rovner, BW, German, PS, Brant, LJ et al. Depression and mortality in nursing homes. JAMA 1991; 265: 993–96.
7Blazer, D. Depression in the elderly. N Engl J Med 1989; 320: 164–66.
8Sulser, F, Janowsky, AJ, Okada, F, Manier, DH, Mobley, PL. Regulation of recognition and action function of norepinephrine (NE) receptor-coupled adenylate cyclase system in brain: implications for the therapy of depression. Neuropharmacology 1983; 22: 425–31.
9Guthrie, SK. Sertraline: a new specific serotonin reuptake blocker. DICP, Ann Pharmacother 1991; 25: 952–61.
10Stark, P, Fulle, RW, Wong, DT. The pharmacologic profile of fluoxetine. J Clin Psychiatry 1985; 46: 713.
11Pujol, JF, Keane, P, McRae, A et al. Biochemical evidence for serotonergic control of the locus ceruleus. In: Garatinni, S, Pujol, JF, Samanin, R eds. Interactions between putative neurotransmitters in the brain. New York: Raven Press, 1978: 401–10.
12Wang, RY, Aghajanian, GK. Collateral inhibition of serotonergic neurons in the dorsal raphe nucleus: pharmacological evidence. Neuropharmacology 1987; 17: 819–25.
13Feuerstein, TJ, Hertting, G. Serotonin (5-HT) enhances hippocampal noradrenaline (NA) release: evidence for facilitatory 5-HT receptors within the CNS. Naunyn Schmiedebergs Arch Pharmacol 1986; 333: 191–97.
14Doogan, DP, Callard, V. Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49 (suppl 8): 4651.
15Shopsin, B, Friedman, E, Gershon, S. Pharachlorphenylalanine reversal of tranylcypramine effects in depressed patients. Arch Gen Psychiatry 1976; 33; 811–19.
16Grimsley, SR, Jann, MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharmacy 1992; 11: 930–57.
17Lemberger, L, Bergstrom, RF, Wolen, RL et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46: 1419.
18Bergstrom, RF, Lemberger, L, Farid, NA, Wolen, RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988; 153 (suppl 3): 4750.
19Mellerup, ET, Plenge, P. High affinity binding of 3H-paroxetine and 3H-imipramine to rat neuronal membranes. Psychopharmacology 1986; 89: 436–39.
20Preskorn, SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 2(94): 2S12S.
21Bayer, AJ, Roberts, NA, Allen, EA et al. The pharmacokinetics of paroxetine in the elderly. Acta Psychiatr Scand 1989; 80 (suppl 350): 8586.
22Lundmark, J, Thomsen, IS, Fjord-Larsen, T et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand 1989; 80 (suppl 350): 7680.
23Haddock, RE, Johnson, AM, Langley, PF et al. Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr Scand 1989; 80 (suppl 350): 2426.
24Kaye, CM, Haddock, RE, Langley, PF et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80 (suppl 350): 6075.
25Tasker, TCG, Kaye, CM, Zussman, BD, Link, CGG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 1989; 80 (suppl 350): 152–55.
26Koe, BK. Preclinical pharmacology of sertraline: a potent and specific inhibitor of serotonin reuptake. J Clin Psychiatry 1990; 51 (suppl B): 1317.
27Johnson, AM. An overview of the animal pharmacology of paroxetine. Acta Psychiatr Scand 1989; 80 (suppl 350): 1420.
28Dunbar, GC. An interim overview of the safety and tolerability of paroxetine. Acta Psychiatr Scand 1989; 80 (suppl 350): 135–37.
29Schmidt, MJ, Fuller, RW, Wong, DT. Fluoxetine, a highly selective serotonin reuptake inhibitor: a review of preclinical studies. Br J Psychiatry 1988; 153 (suppl 3): 4046.
30Fredericson, O-K. Kinetics of citalopram in elderly patients. Psychopharmacology 1985; 86: 253–57.
31Schatzberg, AF. Dosing strategies for antidepressant agents. J Clin Psychiatry 1991; 52 (5 suppl): 1420.
32Altamura, AC, Montgomery, SA, Wernicke, JF. The evidence for 20 mg a day of fluoxetine as the optimal dose in the treatment of depression. Br J Psychiatry 1988; 153 (suppl 3): 109–12.
33Salzman, C. Monoamine oxidase inhibitors and atypical antidepressants. Clin Geriatric Med 1992; 8: 335–48.
34Guthrie, SK. Sertraline: a new specific serotonin reuptake blocker. DICP, Ann Pharmacother 1991; 25: 952–61.
35Berman, I, Sapers, BL, Salzman, C. Sertraline: a new sertonergic antidepressant. Hosp Commun Psychiatry 1992; 43: 671–72.
36Jenner, PN. Paroxetine: an overview of dosage, tolerability, and safety. Int Clin Psychopharmacol 1992; 6 (suppl 4): 6980.
37Feighner, JP, Cohn, JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatry 1985; 46(3): 2025.
38Feighner, JP, Boyer, WF, Meredith, CH, Hendrickson, G. An overview of fluoxetine in geriatric depression. Br J Psychiatry 1988; 153 (suppl 3): 105108.
39Altamura, AC, de Novellis, F, Guercetti, G et al. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res 1989; IX: 391–96.
40Conn, CK, Shrivastava, R, Mendels, J et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51 (12 suppl): 2833.
41Dunner, DL, Cohn, JB, Walshe, T III et al. Two combined, multi-centre double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992; 53 (suppl 2): 5760.
42Guillibert, E, Pelicier, Y, Archambault, JC et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989; 80 (suppl 350): 132–34.
43Wakelin, JS. Fluvoxamine in the treatment of the older depressed patient: double-blind, placebo-controlled data. Int Clin Psychopharmacol 1986; 1: 221–30.
44Phanjoo, AL, Wonnacott, S, Hodgson, A. Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people. Acta Psychiatr Scand 1991; 83: 476–79.
45Schone, W, Ludwig, M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13 (6 suppl 2): 34S39S.
46Wagner, W, Plekkenpol, B, Gray, TE. Review of fluvoxamine safety database. Drugs 1992; 43 (suppl 2): 4854.
47Benfield, P, Ward, A. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 313–34.
48Howard, R, Bandyopadhyay, D. Selective serotonin reuptake inhibitors for the elderly. Int J Geriatric Psychiatry 1992; 8: 627–29.
49Reimherr, FW, Chouinard, G, Cohn, CK et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51 (12 suppl B): 1827.
50Heym, J, Koe, BK. Pharmacology of sertraline: a review. J Clin Psychiatry 1988; 49 (8 suppl): 4045.
51Wurtman, JJ, Wurtman, RJ. Fenfluramine and fluoxetine spare protein consumption while suppressing caloric intake by rats. Science 1977; 198: 1178–80.
52Crews, J, Potts, N, Schreiber, J, Lipper, J. Hyponatremia in a patient treated with sertraline [Letter]. Am J Psychiatry 1993; 150: 1517.
53Belanoff, J, Sheikh, JI. Hyponatremia as a side effect of selective serotonin reuptake inhibitors. Am J Geriatric Psychiatry 1994 (in press).
54Feighner, JP, Boyer, WF. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. Acta Psychiatr Scand 1989; 80 (suppl 350): 125–29.
55Wurtman, JJ. Discussion: conference on sertraline. J Clin Psychiatry 1988; 49 (8 suppl): 7273.
56Cooper, GL. The safety of fluoxetine – an update. Br J Psychiatry 1988; 153 (suppl 3): 7786.
57Byerley, WF, Reimherr, FW, Wood, DR. Fluoxetine, a selective serotonin uptake inhibitor for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988; 8: 112–15.
58Cole, JO. New directions in antidepressant therapy: a review of sertraline, a unique serotonin reuptake inhibitor. J Clin Psychiatry 1992; 53: 333–40.
59Cole, JO, Bodkin, JA. Antidepressant drug side effects. J Clin Psychiatry 1990; 51 (1 suppl): 2126.
60Schweizer, E, Rickeis, K. Clinical overview of serotonin reuptake inhibitors. J Clin Psychiatry 1990; 51 (12 suppl B): 912.
61Fisch, C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985; 46: 4244.
62Buff, DD, Brenner, R, Kirtane, SS, Gilboa, R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991; 52: 174–76.
63Ellison, JM, Milogsky, JE, Ely, E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990; 51: 385–86.
64Halper, JP, Mann, JJ. Cardiovascular effects of antidepressant medications. Br J Psychiatry 1988; 152 (suppl 3): 8798.
65Wernicke, JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46: 5967.
66Mattila, MJ, Saarialho-Kere, U, Manila, M. Acute effects of sertraline, amitriptyline, and placebo on the psychomotor performance of healthy subjects over 50 years of age. J Clin Psychiatry 1988; 49 (8 suppl): 5258.
67Musher, JS. Anorgasmia with the use of fluoxetine [Letter]. Am J Psychiatry 1990; 147: 948.
68Smith, D, Levitte, S. Association of fluoxetine and return of sexual potency in three elderly men. J Clin Psychiatry 1993; 54: 317–19.
69Hwang, AS, Magraw, RM. Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine [Letter]. Am J Psychiatry 1989; 146: 399.
70Cohen, JB, Mahelsky, M, Adler, L [Letter]. More cases of SIADH with fluoxetine. Am J Psychiatry 1990; 147: 948–49.
71Gommare, JH, Edwards, RA. Fluoxetine and hyponatremia [Letter]. N Z Med J 1990; 105: 106.
72Vishvanuth, B, Navalgund, AA, Cosano, W, Nagaland, HA. Fluoxetine as a cause of SIADH [Letter]. Am J Psychiatry 1991; 148: 542–43.
73Goddard, C, Paton, C. Hyponatremia associated with paroxetine [Letter]. BMJ 1993; 306: 143.
74Chun, TP, Vong, SH. Hyponatremia associated with paroxetine [Letter]. BMJ 1993; 306: 143.
75Lipinski, JF Jr, Mallya, G, Zimmerman, P et al. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42.
76Rothschild, AJ, Locke, CA. Re-exposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. J Clin Psychiatry 1991; 52: 491–93.
77Black, B, Uhde, TW [letter]. Acute dystonia and fluoxetine. J Clin Psychiatry 1992; 53: 327.
78Bouchard, RH, Pourcher, E, Vincent, P. Fluoxetine and extra-pyramidal side effects [Letter]. Am J Psychiatry 1989; 146: 1352–53.
79Baldwin, D, Fineberg, N, Montgomery, S. Fluoxetine, fluvoxamine, and extra-pyramidal disorders. Int Clin Psychopharmacol 1991; 6: 5158.
80Hebenstreit, GF, Fellerer, K, Zochling, R, Zentz, A, Dunbar, GC. A pharmacokinetic dose titration study in adult and elderly depressed patients. Acta Psychiatr Scand 1989; 80 (suppl 350): 8184.
81Chouinard, G, Jones, B. No crossover of hypersensitivity between zimelidine and fluoxetine. Can Med Assoc J 1984; 131: 1190.
82Figiel, GS, Krishnan, KRR, Breitner, JC, Nemeroff, CB. Radiologic correlates of antidepressant-induced delirium: the possible significance of basal-ganglia lesions. J Neuropsychiatry 1989; 1: 188–90.
83Hindmarsh, I, Shillingford, J, Shillingford, C. The effects of sertraline on psychomotor performance in elderly volunteers. J Clin Psychiatry 1990; 51 (12 suppl B): 3436.
84Hindmarch, I, Harrison, C. The effects of paroxetine and other antidepressants in combination with alcohol on psychomotor activity related to car driving. Acta Psychiatr Scand 1989; 80 (suppl 350): 4549.
85Sternbach, H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; ii: 850–51.
86Dursun, S, Mathew, VM, Reveley, MA. Toxic serotonin syndrome after fluoxetine plus carbamazepine [Letter]. Lancet 1993; 342: 442–43.
87Pearson, H. Interaction of fluoxetine with carbamazepine [letter]. J Clin Psychiatry 1990; 51: 126.
88Cowen, P, Thompson, C, Roberts, A et al. Selective serotonin reuptake inhibitors. BMJ 1994; 309: 1082–85.

Related content

Powered by UNSILO

The use of selective serotonin reuptake inhibitors in geriatric depression: a review of the literature

  • Richard Marc Patel (a1) and George T Grossberg (a2)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.